Diabetes
One place to start, learn, live and go deeper. MHH connects trustworthy diabetes knowledge from scientific societies, patient organisations and public-health institutions around the world.
Knowledge is useful when it meets people where they are.
At home, at school, at work, in families and communities , health is more than what happens in a clinic.
Photo: Liliana Drew / PexelsNew to diabetes?
Clear, practical places to begin.
Build your knowledge.
EASD Education
More than 80 CME-accredited modules across practical and emerging diabetes topics.
Explore →DIABETES UK · FREELearning Zone
Interactive learning about food, movement, healthcare support and emotional health.
Explore →RSSDI · INDIA · MULTILINGUALRSSDI Patient Education
Patient education across nutrition, exercise, insulin, complications and more in multiple Indian languages.
Explore →IDF KiDS · GLOBALKiDS Resource Hub
Multilingual resources for children, families and schools.
Explore →What can lower risk?
Prevention should never become blame. Type 2 diabetes risk is shaped by genetics, age, environment, access to healthy food, opportunities to move, socioeconomic conditions and other factors , alongside behaviours that people may be able to change.
Diabetes: prevention and population health
WHO's overview includes measures that can help prevent or delay type 2 diabetes and reduce complications.
Read WHO →CDC · TYPE 2 DIABETESPreventing type 2 diabetes
An evidence-based starting point on risk, prediabetes and lifestyle-change programmes.
Explore →MHH principle: Prevention content will focus on evidence and practical options without pretending every person has the same choices, environment or risk.
Photo: Se Ka Wa / PexelsMove for health , and understand why.
Not a list of punishing workouts. This section will connect exercise science with realistic movement for different ages, bodies, abilities and starting points.
Future MHH exercise pieces will explain the evidence behind activities such as walking, resistance training, balance and aerobic exercise , with adaptations rather than one-size-fits-all prescriptions.
For everyday life.
The knowledge that comes from living it.
Clinical guidance matters. So does lived experience.
Insights, stories & perspectives
Writing from an international network of diabetes advocates about daily life, technology, stigma, access and advocacy.
Read →SOUTH AFRICA · LIVED EXPERIENCEBuilding diabetes advocacy from the ground up
A South African advocate's story of global learning and local action.
Read →Care closer to home.
Our November spotlight looks at an African health-system response to severe chronic disease.
Bringing complex chronic care closer to patients
WHO's PEN-Plus approach supports district-level care for severe chronic conditions including type 1 diabetes, helping bridge the gap between primary and specialist care.
Explore the WHO manual →ZASOUTH AFRICADiabetes South Africa
Patient support, education and locally relevant diabetes information.
Explore →IDFAFRICA REGIONIDF Africa network
Regional diabetes organisations, advocacy and resources across the continent.
Explore →Explore more countries and organisations →
Worth knowing in diabetes.
A small selection of developments we think are worth your time , not an attempt to cover every headline. We link to original sources and keep evidence status visible.
Diabetes Doesn't Always Announce Itself
Millions of people live with diabetes without knowing it. Why early action requires both awareness and access to care.
Read the MHH feature →PEER-REVIEWED STUDY · 23 OCTOBER 2026Could AI eye screening help close an access gap?
In a prospective study of 397 young people with diabetes, offering autonomous AI eye exams during diabetes visits brought screening completion to about 98–99.5% across White and non-White participants.
Read the original study →PHASE 3 · TOPLINE COMPANY RESULTS · 28 OCTOBER 2026Retatrutide vs Ozempic: promising results, important caveats
Lilly reports greater A1C reduction and more than twice the average weight loss with investigational retatrutide versus Ozempic 2 mg at 80 weeks. Full peer-reviewed results are not yet available, and retatrutide is not approved.
See the original results →ADA/EASD CONSENSUS · 15 SEPTEMBER 2026Type 1 diabetes care gets a major update
The updated adult type 1 diabetes consensus brings new technology, complications, cardiovascular risk, obesity, psychosocial care and disease-modifying treatment into one modern framework.
Read the consensus report →WHO AFRICA · SEPTEMBER 2026PEN-Plus: taking severe chronic-disease care beyond specialist centres
The WHO Africa operational manual sets out how countries can bring care for conditions including type 1 diabetes closer to people through district-level services.
Read the WHO manual →Go beyond the headline.
Start with the evidence. Then understand what it says, why it matters and what it doesn't tell us.
Type 2 diabetes care is changing
Five things worth knowing from the new consensus report.
Read the MHH Summary →MHH EXPLAINER · IDF ATLAS 2025Five things the IDF Diabetes Atlas tells us
589 million adults, 252 million undiagnosed and an especially important story for Africa.
Read the explainer →We look for credible authorship, clear purpose, useful access and relevance to a defined audience. We prefer original sources and deliberately look beyond a single country or health system.
MHH is educational and does not replace medical advice from your healthcare team.